Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis

被引:0
|
作者
Do, Michael M. [1 ]
Fleury, Jacklyn A. [2 ]
Morgan, Grant P. [1 ]
Zimmerman, Lisa Hall [1 ]
Hanni, Claudia M. [1 ]
Sulaiman, Hiba [1 ]
Lutz, Mark F. [1 ]
机构
[1] Corewell Hlth William Beaumont Univ Hosp, Dept Pharm Serv, 3601 West 13 Mile Rd, Royal Oak, MI 48073 USA
[2] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI USA
关键词
diabetic ketoacidosis; insulin; hyperglycemia; GLARGINE; MANAGEMENT;
D O I
10.1177/10600280241278371
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Evidence is inconclusive if early administration of subcutaneous (SQ) long-acting insulin (LAI) in management of diabetic ketoacidosis (DKA) improves outcomes. Objective: This study compares early versus late administration of SQ LAI in time to DKA resolution. Methods: This single-center, retrospective study included patients with DKA who received >= 12 hours of continuous intravenous insulin (CIVI) with LAI overlap. Patients were compared based on LAI administration time to CIVI initiation: Early (<12 hours) versus Late (>= 12 hours). The DKA resolution is defined as blood glucose < 200 mg/dL and 2 of the following: anion gap < 12 mEq/L, pH > 7.35, or serum carbon dioxide >15 mEq/L. Outcomes included time to DKA resolution, length of stay (LOS), CIVI duration, and adverse events. Results: A total of 27 patients were included in each group. Baseline characteristics were similar between both groups. There was no difference in time to DKA resolution, Early = 17.6 (13.9-26.8) hours versus Late = 19.2 (17.1-32.1) hours, P = 0.16. The Early group had shorter CIVI duration (Early = 19.5 +/- 10.3 hours vs Late = 25.6 +/- 8.4 hours, P = 0.02) and received less intravenous (IV) fluids in the first 36 hours (Early = 4.04 +/- 2.12 L vs Late = 5.85 +/- 2.24 L, P = 0.004). No differences were identified with adverse events, including hypoglycemia, or LOS. Conclusion and Relevance: Administration of SQ LAI < 12 hours did not decrease time to DKA resolution or LOS. Patients in the Early group had received a lower dose of LAI, shorter duration of CIVI infusion, and required less IV fluids within 36 hours of admission. This study supports the need for further research to determine the potential benefits of administering SQ insulin early in managing DKA.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] EVALUATION OF INSULIN GLARGINE EARLY ADMINISTRATION IN THE ACUTE MANAGEMENT OF DIABETIC KETOACIDOSIS
    Mohamed, Adham
    Ploetz, Jeannette
    Hamarshi, Majdi
    CRITICAL CARE MEDICINE, 2020, 48
  • [22] Long-acting insulin analogues
    Holt, R
    DIABETES OBESITY & METABOLISM, 2003, 5 (04): : 270 - 270
  • [23] A NEW LONG-ACTING INSULIN
    不详
    BMJ-BRITISH MEDICAL JOURNAL, 1953, 1 (4804): : 266 - 266
  • [24] Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
    Lim, Beng Leong
    Lee, Wei Feng
    Lee, Berlin
    Chung, Yan Ee Lynette
    Loo, Kee Vooi
    BMJ OPEN, 2023, 13 (02):
  • [25] Editorial: Glargine, a new long-acting insulin analog for diabetic cats
    Rand, J
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2006, 20 (02) : 219 - 220
  • [26] An Audit of the Adherence of Long-acting Insulin Administration during DKA in SVUH
    Higgins, Sarah
    Crowley, Rachel
    IRISH JOURNAL OF MEDICAL SCIENCE, 2024, 193 : S211 - S212
  • [27] Long-acting Insulin Analogues and Diabetic Retinopathy: A Retrospective Cohort Study
    Lin, Jen-Chieh
    Shau, Wen-Yi
    Lai, Mei-Shu
    CLINICAL THERAPEUTICS, 2014, 36 (09) : 1255 - 1268
  • [29] Insulin detemir: A long-acting insulin product
    Jones, Melissa C.
    Patel, Mallika
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (24) : 2466 - 2472
  • [30] Diabetic ketoacidosis in a patient with acromegaly and central diabetes insipidus treated with octreotide long-acting release
    Inaba H.
    Funahashi T.
    Ariyasu H.
    Iwakura H.
    Furuta H.
    Nishi M.
    Akamizu T.
    Diabetology International, 2017, 8 (2) : 237 - 242